Didier has 30 years’ experience in drug delivery using colloids, ranging from basic research to clinical trials. He has collaborated with BioChem Pharma, GSK, Sanofi Pasteur and Chiron-Novartis on the evaluation of nasal vaccine using nanotechnologies. As an international expert in nanomedicine, he presided at the French Society for Controlled Release, was a board member of the French Society of Nanomedicine, and has over 110 international publications and 23 patents.
After a PhD on drug targeting in collaboration with the World Health Organization, Didier developed a patented technology for vaccine applications based on polysaccharidic nanoparticles with a phospholipid bi-layer.
His experience, innovative research and patented technology are at the heart of Vaxinano.
Angelo joined VAXINANO in May 2019 as a project manager, with 7 years of experience as an engineer and then R&D manager in a start-up specialized in microbiology and fermentative metabolites. He successfully managed the different key R&D steps starting with the characterization of fermentative metabolites, the design and follow-up of pre-clinical studies, the standardization of production and the transfer to a pharmaceutical structure for marketing .
Within Vaxinano, he is now in charge of monitoring and coordinating vaccine development projects.
He holds a PhD in microbiology, immunology, virology and parasitology from the University of Lille and a Master's degree in Biotechnology with a specialization in genomics and proteomics from the University of Lille.
